Drug Most active stocks: Pfizer Inc. (NYSE:PFE), Merck & Co (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Bristol-Myers Squibb (NYSE:BMY)

Posted by on Apr 11, 2014

Pfizer Inc. (NYSE:PFE) has reported success for its experimental Bococizumab in reducing LDL-C cholesterol in a Phase 2 trial involving patients who are at risk for cardiovascular events. This is a new drug formulation for patients whose high cholesterol level isn’t controllable with traditional statin therapy. It has reported success in Phase 3 study of ALK-inhibitor Xalkori (crizotinib), in demonstrating progression-free survival in patients with advanced non-squamous non-small cell lung cancer (NSCLC). Pfizer Inc. (NYSE:PFE) shares after opening at $31.38 moved to $31.43 on last trade day and at the end of the day closed at $30.61. Company price to sales ratio in past twelve months was calculated as 3.79 and price to cash ratio as 6.04. Pfizer Inc. (NYSE:PFE) showed a negative weekly performance of -5.52%.

Merck & Co., Inc. (NYSE:MRK) announced successful results from a clinical trial of its experimental Hepatitis C drug. The drug maker reported having cured 98% of the patients treated with its once a day pill, which is basically a two drug combination therapy. The results were noticed at a mid—stage study the company presented at the European Association for the Study of the Liver that was held in London. The therapy has reported exhibiting little side effects. Merck & Co., Inc. (NYSE:MRK) shares fell -2.19% in last trading session and ended the day on $55.85. MRK return on equity ratio is recorded as 12.10% and its return on assets is 5.60%. Merck & Co., Inc. (NYSE:MRK) yearly performance is 22.50%.

Johnson & Johnson (NYSE:JNJ) has received a consensus recommendation of “Hold” from the seventeen ratings firms that are presently covering the company, American Banking News reports. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and six have assigned a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $76.92. Johnson & Johnson (NYSE:JNJ) shares moved down -2.44% in last trading session and was closed at $96.54, while trading in range of $96.52-$98.93. Johnson & Johnson (NYSE:JNJ) year to date performance is 6.16%.

A combination of two anti-viral drugs developed by Bristol-Myers Squibb Co (NYSE:BMY) cured 90 percent of previously untreated hepatitis C patients and 82 percent of those who failed to respond to prior therapy, according to results from a late stage study presented on Thursday.The Phase III trial of more than 700 patients called Hallmark-Dual tested a combination of Bristol’s daclatasvir and asunaprevir over 24 weeks of therapy in patients with genotype 1b of the virus that causes progressive liver disease. Bristol-Myers Squibb Co (NYSE:BMY) weekly performance is -3.11%. On last trading day company shares ended up $49.29. Bristol-Myers Squibb Co (NYSE:BMY) distance from 50-day simple moving average is -5.90%. Analysts mean target price for the company is $55.12.

Leave a Reply

Your email address will not be published. Required fields are marked *